Friday, July 10, 2026

Drug profile · INN

lasofoxifene

lasofoxifene (FABLYN) is a estrogen receptor modulator.

EMA: unknown Genito-urinary system and sex hormones (G03) G03
Patents linked 0
Pipeline programs 3
News articles 1
Drug details — lasofoxifene
Class
Genito-urinary system and sex hormones (G03)
Route
Patents
0
Programs
3
Data quality
0.83

Quick answer

lasofoxifene (FABLYN) is a estrogen receptor modulator.

Key facts

INN lasofoxifene
Brand FABLYN
Mechanism Estrogen receptor modulator
Target Estrogen receptor
Therapeutic class Genito-urinary system and sex hormones (G03)
ATC code G03

Mechanism of action

Estrogen receptor modulator

Primary target: Estrogen receptor

Approval history

Authority Status Date
EMA unknown

Recent coverage

Pipeline programs

  1. SMX 22-002 Phase 3 · Anaxis Pharma · Locally advanced or metastatic breast cancer
  2. lasofoxifene Phase 3 · LIGAND PHARMACEUTICALS · Osteoporosis
  3. Lasofoxifene Phase 2 · LIGAND PHARMACEUTICALS · Bone Loss

Related & competitor drugs

  1. apomorphine Genito-urinary system and sex hormones (G04)
  2. estradiol Estrogen receptor alpha agonist
  3. estradiol valerate Estrogen receptor alpha agonist
  4. estrogens, conjugated synthetic a Estrogen receptor agonist
  5. estropipate Estrogen receptor alpha agonist
  6. ethinyl estradiol Estrogen receptor alpha agonist

Frequently asked questions

What is lasofoxifene?

lasofoxifene (FABLYN) is a estrogen receptor modulator.

What is the brand name for lasofoxifene?

FABLYN is a marketed brand name for lasofoxifene. Check FDA Drugs@FDA for the current US label holder and prescribing information.